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SUMMARY
Background
Irritable bowel syndrome with constipation (IBS-C) signiﬁcantly decreases
quality of life and the ability to perform daily living activities.
Aim
To demonstrate the long-term safety, tolerability and patient outcomes of
lubiprostone in patients with IBS-C.
Methods
This extension study enrolled 522 IBS-C patients who had completed one
of two randomised phase 3 studies. All enrolled patients received open-label
lubiprostone orally for 36-weeks (8 mcg, twice daily). The primary objective
was the assessment of long-term safety and tolerability, monitored via
adverse events (AEs), laboratory parameters and vital signs. Additional out-
come endpoints included monthly responder rates and patient evaluations
of IBS-C symptom severity and impact on quality of life.
Results
The evaluable safety population comprised of 520 patients; 476 of which had
patient reported outcome data available. The overall safety proﬁle of lubipro-
stone during this study was similar to that observed in the preceding phase 3
studies. The most common AEs were diarrhoea (11.0%), nausea (11.0%), uri-
nary tract infection (9.0%), sinusitis (9.0%) and abdominal distention (5.8%).
Diarrhoea and nausea were the most common treatment-related AEs. No seri-
ous AEs were considered treatment-related. Seventeen patients discontinued
due to a treatment-related AE, of which diarrhoea and nausea accounted for six
(1.2%) and three (0.6%) respectively. For responder rates and patient-evaluated
parameters (n = 476), all groups experienced signiﬁcant improvements from
baseline, with initial improvements maintained throughout the study.
Conclusion
In patients with irritable bowel syndrome with constipation, lubiprostone
8 mcg twice daily was found to be safe and well tolerated over 9–13 months
of treatment.
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INTRODUCTION
Irritable bowel syndrome (IBS) is deﬁned by the pres-
ence of abdominal pain or discomfort that occurs in
association with altered bowel habits over a period of at
least 3 months.1, 2 IBS is a common disorder with esti-
mated prevalence rates ranging from 9% to 22% in the
USA3 and accounting for 25–50% of referrals to gast-
roenterologists.4 In most parts of the world, IBS occurs
more commonly amongst women than men with an esti-
mated prevalence ratio of roughly 2:1.5
Individuals with IBS have substantial decrements in
their quality of life as well as their ability to perform
activities of daily living.2 Indeed, patients with IBS, com-
pared with those with gastroesophageal reﬂux disease
(GERD), report signiﬁcantly greater impairments in their
ability to carry out daily activity (P = 0.01) and work
activity (P < 0.001), and experience greater work loss
(P = 0.003).6 IBS patients who have more severe symp-
toms also often suffer from coexisting anxiety, depres-
sion, somatization disorders or poor coping skills, and
commonly have other co-morbid conditions such as ﬁ-
bromyalgia, migraine headaches, interstitial cystitis and
temporomandibular joint syndrome.2 The economic bur-
den of IBS in the USA is estimated to be $20–25 billion
annually.2, 6
The diagnosis of IBS is commonly based on criteria
established by the Rome Committee.1 IBS is a clinically
heterogeneous condition with a broad spectrum of bowel
related complaints. The Rome Committee suggests that
IBS patients be subgrouped, based upon stool consis-
tency, into those with predominantly constipation (IBS-
C), diarrhoea (IBS-D), or a mixture of both (IBS-M).
Such subgrouping assists in the appropriate selection of
diagnostic testing and treatment.
There are limited treatment options for patients with
IBS-C. Although ﬁbre supplements, probiotics and laxa-
tives are commonly utilised, there is little evidence to
support their efﬁcacy for the global symptoms of IBS-C.2
Lubiprostone, a member of a class of compounds
called prostones, is currently an approved therapy in the
U.S.A for the treatment of men and women with chronic
idiopathic constipation, and women with IBS-C. Data
from two randomised, placebo-controlled, multicenter
(130 US sites), double-blind phase 3 trials that enrolled
patients with IBS-C in accordance with the Rome II cri-
teria, found that lubiprostone 8 mcg administered orally
twice daily for 12–16 weeks produced a signiﬁcantly
greater percentage of overall responders compared with
placebo (17.9% vs. 10.1%, P = 0.001).7 The current 36-
week extension study enrolled eligible patients from
these previous two phase 3 trials, and further investi-
gated the long-term safety and tolerability of lubipro-
stone in the treatment of IBS-C.
METHODS
Study design
This study represents a follow-on open-label, 36-week
clinical trial of lubiprostone 8 mcg twice daily to investi-
gate the long-term safety and tolerability of lubiprostone
in the treatment of IBS-C. Patients who completed one
of two phase 3 studies8 and were at least 70% compliant
with the study medication were eligible to enrol in this
extension study. In the ﬁrst phase 3 study [SIB-0431
(NCT00380250)], patients received treatment with pla-
cebo twice daily for 16 weeks or lubiprostone 8 mcg
twice daily for 12 weeks, with the latter group then
receiving an additional 4-week treatment with either
continued lubiprostone or placebo (randomised with-
drawal period) (Figure 1a). In the second phase 3 study
[SIB-0432 (NCT00399542)], patients were treated for
12 weeks with placebo twice daily or lubiprostone 8 mcg
twice daily (Figure 1b). Rollover to the extension study
was available to any patient enrolled in the phase 3 stud-
ies regardless of response status. However, screening for
the extension study was stopped when it was conﬁrmed
that least the target of 500 enrolled patients would be
met. For illustrative purposes, patients were stratiﬁed
into one of three enrolment groups based on their treat-
ment allocation in the preceding phase 3 trial, as follows:
(i) Placebo rollover patients: Patients who received
placebo in SIB-0431 or SIB-0432 before enrolling in the
current extension study (Figure 1a and b). These patients
are referred to as placebo/lubiprostone (P/L) patients;
(ii) Lubiprostone/placebo rollover patients: Patients
who received lubiprostone during Treatment Period
Phase I of SIB-0431 and placebo during Treatment Per-
iod Phase II of SIB-0431 before enrolling in the current
study (Figure 1a). These patients are referred to as lubi-
prostone/placebo/lubiprostone (L/P/L) patients; and
(iii) Lubiprostone rollover patients: Patients who
received lubiprostone during Treatment Period Phases I
and II throughout SIB-0431 or lubiprostone during SIB-
0432 before enrolling in the current study (Figure 1a
and b). These patients are referred to as lubiprostone/
lubiprostone (L/L) patients.
The duration of the active treatment period differed
depending on a patient’s treatment assignment in the
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earlier study (Figure 1a and b). As such, if a patient had
been in the placebo group (P/L), the patient’s data are
summarised only from the extension study for a total of
36 weeks of data. If a patient had been in the lubiprostone
group (SIB-0432; L/L) or in the lubiprostone/placebo
group (SIB-0431; L/P/L), the patient’s data from the earlier
Figure 1 | (a) Schematic of study SIB-0431. (b) Schematic of study SIB-0432.
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study would be combined with the data from this exten-
sion study for a total of 48 weeks of data. Finally, if a
patient had been in the lubiprostone group (SIB-0431; L/
L), data would be combined from both studies for a total
of 52 weeks of data.
This current clinical trial was performed in accordance
with the Declaration of Helsinki. Written informed con-
sent was obtained from each patient prior to undergoing
any procedure and the study protocols and any amend-
ments were approved by the institutional review board at
each study site.
Open-label treatment and procedures
All patients were treated with lubiprostone 8 mcg
administered twice daily. A reduction to once-daily dos-
ing was allowed at the discretion of the investigator if
the patient experienced severe nausea or severe diarrhoea
for more than two consecutive days, or if the patient
experienced some other signiﬁcant adverse event.
Patients returned for ofﬁce visits at weeks 4, 12, 20, 28
and 36; with telephone follow-up performed at weeks 8,
16, 24, 32 and 2 weeks following the completion of the
extension study (week 38).
In the phase 3 studies, as well as during this extension
study, patients were instructed to maintain a stable diet
that included no signiﬁcant changes in their consumption
of liquids or ﬁbre. They were also instructed not to alter
their baseline level of physical activity or to take any new
medications for constipation signs and symptoms
through the phase 3 or extension study periods. The use
of concomitant medications affecting bowel function were
not permitted with the exception of 10 mg Dulcolax sup-
pository (bisacodyl, Boehringer Ingelheim GmbH, Ingel-
heim Rhein, Germany), which was allowed as rescue
medication if the patient had not passed a bowel move-
ment for at least 3 days. If bisacodyl was not effective,
patients could then administer a Fleet enema (dibasic
sodium phosphate and monobasic sodium phosphate; C.
B. Fleet, Lynchburg, VA, USA). If both of these options
were unsuccessful, an alternative medication could be
prescribed at the discretion of the investigator, with the
exception of tegaserod maleate. Rescue medications were
utilised to affect an immediate bowel movement and not
for continuous therapy during the treatment period.
Safety and tolerability assessments
The safety of lubiprostone was assessed by monitoring the
incidence, severity and relationship to study medication of
all adverse events (AEs) and serious AEs (SAEs). These
events included those reported by the patient or by the
investigator. The safety of lubiprostone was assessed at
each ofﬁce visit and telephone interview. Patients were
prompted to report any changes in their health status
while on therapy, including signs and symptoms. AEs were
graded by the investigator for intensity and rated as mild
(transient symptoms with no interference to daily activi-
ties), moderate (marked symptoms with moderate interfer-
ence to daily activities) or severe (considerable interference
to daily activities). The investigator also graded the events
for their relationship to study medication as unrelated,
unlikely, possible, or probable, and recorded the frequency
of the AE as once, intermittent, or continuous.
Tolerability was assessed by the patient’s ability to
continue treatment without experiencing a treatment-
related AE leading to discontinuation or dose reduction
of lubiprostone. Patients who discontinued treatment or
dose reduced prior to completing the study were consid-
ered not to have tolerated lubiprostone.
Blood samples for haematology and biochemistry and
urine samples for urinalysis were collected at regular
intervals throughout the study period (baseline and
weeks 4, 12, 20, 28 and 36). Vital signs, weight, body
mass index and physical examinations were also regu-
larly assessed during ofﬁce visits.
Patient outcome assessments
In the phase 3 and extension studies, the effect of lubi-
prostone treatment on the symptoms of IBS-C was eval-
uated on a monthly basis using information from patient
diary entries. Data from the baseline period of each ini-
tial phase 3 study were used as the baseline for the
extension study. Responder status was calculated from
the weekly assessments of symptom relief. Symptom
relief was assessed in response to the electronic diary
question of ‘How would you rate your relief of IBS
symptoms (abdominal pain/discomfort, bowel habits and
other IBS symptoms) over the past week compared to
how you felt before you entered the study?’ using a
7-point balanced scale (signiﬁcantly relieved = 1, moder-
ately relieved = 2, a little bit relieved = 3, unchanged
= 4, a little bit worse = 5, moderately worse = 6 or sig-
niﬁcantly worse = 7). A patient was considered a
monthly responder if: their symptoms were at least mod-
erately relieved for all 4 weeks within the month, or sig-
niﬁcantly relieved for at least 2 weeks within the month,
and provided that there were no ratings of moderately
or severely worse, that the patient did not discontinue
treatment during the 4 week period due to a lack of
efﬁcacy, and that the per cent of days of rescue medica-
tion use did not increase compared with baseline.
590 Aliment Pharmacol Ther 2012; 35: 587-599
ª 2012 Blackwell Publishing Ltd
W. D. Chey et al.
Patient evaluations of symptoms of abdominal dis-
comfort/pain, abdominal bloating, SBM and BM fre-
quency rates, stool consistency, bowel straining,
constipation severity and symptom relief were also
recorded in the diaries. Patients assessed these symptoms
(with the exception of stool consistency) using the scale
of 0 = absent, 1 = mild, 2 = moderate, 3 = severe and
4 = very severe. Stool consistency was rated as 0 = very
loose (watery), 1 = loose, 2 = normal, 3 = hard and
4 = very hard (little balls).
Patients also completed the IBS-Quality-of-Life (IBS-
QOL) questionnaire at each ofﬁce visit.9, 10 In this vali-
dated questionnaire, patients selected 1 of 5 responses to
34 questions regarding the change from baseline in over-
all quality of life and more speciﬁc items in the categories
of dysphoria, interference with activity, body image,
health worry, food avoidance, social reaction and sexual
relationship. Higher scores indicated better quality of life.
Statistical analyses
The sample size in this extension study was determined
based on the International Conference on Harmonisation
(ICH) guidelines, which state that 300–600 patients trea-
ted for 6 months is adequate to characterise the pattern
of AEs over time, and that 100 patients treated over
12 months should be sufﬁcient to assess the true cumu-
lative incidence of SAEs and events that increase in
severity over time.
Safety analyses were performed using data from all
patients who received at least one dose of lubiprostone
during the extension study (safety evaluable population).
All AEs were coded using the Medical Dictionary for
Drug Regulatory Activities (MedDRA; Northrop Grum-
man Corporation, Chantilly, VA, USA) version 7.0 ter-
minology and AE incidences were summarised by
system-organ class and preferred term and by enrolment
group. AEs were captured while the patient was receiving
study medication or within 7 days of discontinuing study
medication. AEs were summarised by the number and
per cent of patients who experienced at least one AE,
who experienced at least one treatment-related AE, who
experienced at least one severe AE, who experienced at
least one SAE, who withdrew from the study due to an
AE and who died during the study. For clinical labora-
tory data, descriptive statistics and pre-treatment vs.
post-treatment shift tables (with classes for below, within
and above normal ranges) were generated.
Patient demographics and baseline characteristics data
were summarised by enrolment group with descriptive
statistics. Assessment of actual drug exposure was made
for each enrolment group. Exposure was based on the
number of days of lubiprostone use (ﬁrst to last dose).
Outcome analyses were determined in the intent-to-
treat (ITT) population, deﬁned as all safety evaluable
patients who had at least one treatment-period weekly
diary entry. For data collected in the diary, the baseline
value was the average of the entries from the 28 days
before Visit 2 in the preceding study (SIB-0431 or SIB-
0432). For nondiary data, the baseline value was the
most recently collected value before the ﬁrst administra-
tion of study drug in the preceding study (SIB-0431 or
SIB-0432). Responder rates were based on the patient’s
evaluation of symptom relief and were summarised for
all months. The SBM frequency rate was deﬁned as the
weekly SBM rate, which was determined from the weekly
SBM question. The monthly SBM rate was the average
weekly rate over the 4-week period during the month.
Values, changes and per cent changes from baseline in
constipation symptoms and the IBS-QOL questionnaire
at each month were summarised. Mean changes from
baseline in IBS-C sign and symptom ratings and the
IBS-QOL questionnaire were analysed using the paired t-
test if the distribution was found to be normal. Other-
wise, the Wilcoxon signed-rank test was used. When pre-
sented in ﬁgures conﬁdence intervals of 95% were used.
At Month 4, the three groups were combined in analyses
of responder outcome, as all patients received lubipro-
stone beyond this point. Multiple imputation was used
to assess the effect on response rates for drop-outs that
occurred through the follow-up period. The response
endpoint is binary, so logistical regression multiple
imputation with 25 replications was used. The response
rate at each month was then averaged across the 25
datasets providing complete data at each month. Kaplan
–Meier product-limit method was used to analyse time
to nausea. Repeated time-to-event analysis for repeated
nausea episodes was used to examine the effect of dura-
tion of lubiprostone exposure.11 All tests of change from
baseline were two-tailed at a signiﬁcance level of a =
0.05 and tested the null hypothesis that the change was
equal to zero. Because this is an open-label trial, no
inferential analyses comparing enrolment groups were
performed.
RESULTS
Patient enrolment and disposition
The ﬁrst patient was enrolled into the extension study on
26 September 2005 and the last patient completed the
study on 20 November 2006. Of the 1171 patients enrolled
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into the two phase 3 studies, a total of 522 patients
(48.7%) were enrolled into the extension study, of which
520 received open-label lubiprostone and comprised the
evaluable safety population (Figure 2). Approximately
66% of the 522 patients (n = 342) had received lubipro-
stone treatment during the previous phase 3 studies (L/L
+ L/P/L groups); 34% (n = 180) comprised the P/L group.
Nearly 60% of patients completed the extension study
(304/520, 58.2%) with the proportion of completers being
greatest in the P/L group (62.8%) and lowest in the L/P/L
group (47.5%). A total of 218 patients (41.8%) prematurely
discontinued treatment. Lack of efﬁcacy accounted for
18.1% (94 patients) dropping out of the study. Twenty-
one (4%) patients discontinued due to AEs. Factors unre-
lated to treatment were the primary reason for dropping
out of the study (103 patients, 19.8%).
Mean overall compliance in the safety evaluable popu-
lation was 95.3% and differed little among the enrolment
groups. Fifteen patients overall (2.9%) were <70% com-
pliant with the dosing regimen. Dose reduction to once-
daily dosing occurred in 7.9% of subjects overall (9.7%
for the P/L group vs. 7.5% for the L/P/L group vs. 6.9%
for the L/L group).
Drug exposure was assessed via the median number
of days in the treatment period. Drug exposure was simi-
lar among L/P/L and L/L patients (335 and 336 days
respectively), and less for the P/L patients, who did not
receive lubiprostone until the start of the extension study
(252 days).
Patient demographics and disease status
characteristics
Patient demographics were similar across the L/L, L/P/L
and P/L groups (Table 1), with patients being predomi-
nately female (92.9%) and Caucasian (79.8%) with a mean
age of 47.2 years (range 21 to 82). Among the 476
patients who comprised the ITT population (patients with
at least one diary entry), baseline period disease status
(abdominal discomfort/pain, abdominal bloating, consti-
pation severity, weekly SBM frequency, stool consistency,
SBM bowel straining and IBS overall QoL) were generally
similar across all enrolment groups (Table 2). During the
extension study, at least one rescue medication was
required by 31.5% of patients (164/520), with the use of
rescue medications among the few patients in the P/L
arm being lower (9.5%, n = 17) than that in either the
L/P/L (47.5%, n = 38) or L/L arms (41.8%, n = 109). The
most common rescue medication was Bisacodyl (n = 155;
29.8%). Some patients also reported the use of a Fleet
(n = 39; 7.5%) enema. No other rescue medication was
used by more than 2% of the total population.
Figure 2 | Patient ﬂow and follow-up during the extension study. Of the 522 patients who enrolled in the open-label
extension study, 520 comprised the safety evaluable population and 476 comprised the intent-to-treat population.
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Incidence of adverse events
Overall, 68.7% of patients reported at least one AE and
25.4% reported at least one treatment-related AE
(Table 3), with the incidence being similar across the
groups.
Among all reported AEs, infection and infestation
(36.3%) and gastrointestinal disorders (36.2%) were the
most commonly reported system-organ class AEs. As
summarised in Table 4, the most common AEs that were
reported by at least 5% of patients were diarrhoea
(11.0%), nausea (11.0%), urinary tract infection (9.0%),
sinusitis (9.0%), abdominal distension (5.8%) and head-
ache (5.0%).
Ten patients (1.9%) reported 11 SAEs during the
study (three with reproductive system and breast disor-
ders; two each with musculoskeletal & connective tissue
disorders and nervous system disorders; and one each
with gastrointestinal disorders; injury, poisoning and
procedural complications; general disorders; and renal
and urinary disorders system categories). None of the 11
SAEs were considered treatment-related and no patients
died during the study.
Table 1 | Patient demographics by enrolment group
Characteristic
P/L
(N = 179)
L/P/L
(N = 80)
L/L
(N = 261)
Total
(N = 520)
Age (years)
Mean 48.4 46.0 46.7 47.2
s.d. 12.9 10.0 12.5 12.3
Gender, n (%)
Female 165 (92.2) 78 (97.5) 240 (92.0) 483 (92.9)
Male 14 (7.8) 2 (2.5) 21 (8.0) 37 (7.1)
Race, n (%)
American Indian/Alaska Native/Asian 1 (0.6) 0 (0.0) 2 (0.8) 3 (0.6)
Black/African American 18 (10.1) 10 (12.5) 31 (11.9) 59 (11.3)
Caucasian 146 (81.6) 60 (75.0) 209 (80.1) 415 (79.8)
Hispanic/Latino 13 (7.3) 10 (12.5) 19 (7.3) 42 (8.1)
Others 1 (0.6) 0 (0.0) 0 (0.0) 1 (0.2)
Table 2 | Bowel signs and symptoms at baseline in intent-to-treat population
Enrolment group
IBS-C sign/symptom
P/L
(N = 167)
L/P/L
(N = 71)
L/L
(N = 238)
Total
(N = 476)
Abdominal discomfort/pain 100% 100% 99.6% 99.8%
Discomfort/pain improves after BMs 97.6% 88.7% 93.2% 94.1%
Discomfort/pain associated with BM frequency 85.0% 91.5% 92.8% 89.9%
Discomfort/pain associated with stool consistency 98.8% 98.6% 95.3% 97.0%
<3 BMs per week 92.8% 97.2% 96.6% 95.4%
Hard/Lumpy stools 98.2% 100% 98.3% 98.5%
Straining during BMs 99.4% 100% 98.3% 98.9%
Abdominal discomfort/pain, mean (s.d.) 2.12 (0.64) 2.09 (0.61) 2.09 (0.67) 2.10 (0.65)
Abdominal bloating, mean (s.d.) 2.31 (0.65) 2.31 (0.58) 2.27 (0.68) 2.29 (0.66)
Constipation severity, mean (s.d.) 2.29 (0.64) 2.27 (0.57) 2.22 (0.66) 2.25 (0.64)
Weekly SBM frequency, mean (s.d.) 3.76 (3.44) 3.73 (4.50) 3.86 (3.63) 3.80 (3.70)
SBM stool consistency, mean (s.d.) 2.73 (0.66) 2.78 (0.53) 2.83 (0.68) 2.79 (0.65)
SBM bowel straining, mean (s.d.) 2.39 (0.72) 2.35 (0.78) 2.37 (0.72) 2.38 (0.73)
IBS overall quality of life, mean (s.d.) 55.9 (21.7) 55.6 (22.3) 56.0 (20.9) 55.9 (21.4)
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The most common system-organ class for treatment-
related AEs was the gastrointestinal system (21%). Treat-
ment-related AEs that occurred in more than 1% of
patients overall included diarrhoea (6.5%), nausea
(6.3%), abdominal distension (3.7%), abdominal pain
(2.9%), ﬂatulence (2.1%), upper abdominal pain (1.9%),
headache (1.5%), dizziness (1.3%) and vomiting (1.2%).
Among the 520 enrolled, the number of patients with
treatment-related diarrhoea and nausea events reported
as severe were 4 (0.8%) and 1 (0.2%) respectively
(Table 5).
Of the total 1253 reported AEs, 257 (20.5%) were
treatment-related, 45 of which were diarrhoea and 44
nausea. The majority of treatment-related reports of
diarrhoea (89%) and nausea (98%) were mild to moder-
ate in severity, and none of the treatment-related reports
of diarrhoea and nausea were considered SAEs (Table 6).
The incidence rate and severity of diarrhoea and nausea
were similar across all groups. In addition, the total
number of patient days during the study was
128 052 days. The diarrhoea event rate and treatment-
related diarrhoea event rate were 0.60 and 0.35 per 1000
patient days respectively. The nausea event rate and
treatment-related nausea event rate were 0.57 and 0.34
per 1000 patient days respectively.
Of the 520 patients enrolled in the study, 21 patients
discontinued due to AEs, the most common events were
diarrhoea (n = 7; 1.3%), nausea (n = 4; 0.8%), abdomi-
Table 3 | Overall summary of adverse events by enrolment group
Enrolment group
Disposition
P/L
(N = 179)
n (%)
L/P/L
(N = 80)
n (%)
L/L
(N = 261)
n (%)
Total
(N = 520)
n (%)
Patients reporting at least one AE 110 (61.5) 58 (72.5) 189 (72.4) 357 (68.7)
Patients reporting at least one treatment-related AE 44 (24.6) 21 (26.3) 67 (25.7) 132 (25.4)
Patients reporting at least one severe AE 20 (11.2) 9 (11.3) 35 (13.4) 64 (12.3)
Patients reporting at least one serious AE 1 (0.6) 3 (3.8) 6 (2.3) 10 (1.9)
Patients reporting at least one treatment-related serious AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE, adverse event.
Table 4 | Summary of common treatment-emergent adverse events ( 5% of patients) by body system
Enrolment group
Treatment-emergent adverse event P/L (N = 179) L/P/L (N = 80) L/L (N = 261) Total (N = 520)
Urinary tract infection (%) 11 (6.1) 12 (15.0) 24 (9.2) 47 (9.0)
Sinusitis (%) 15 (8.4) 5 (6.3) 27 (10.3) 47 (9.0)
Nausea (%) 17 (9.5) 5 (6.3) 35 (13.4) 57 (11.0)
Diarrhoea (%) 19 (10.6) 9 (11.3) 29 (11.1) 57 (11.0)
Abdominal distension (%) 9 (5.0) 2 (2.5) 19 (7.3) 30 (5.8)
Headache (%) 7 (3.9) 3 (3.8) 16 (6.1) 26 (5.0)
Table 5 | Summary of subjects with diarrhoea and nausea treatment-related adverse events by severity
Diarrhoea Nausea
Severity*
P/L
(N = 179)
L/P/L
(N = 80)
L/L
(N = 261)
Total
(N = 520)
P/L
(N = 179)
L/P/L
(N = 80)
L/L
(N = 261)
Total
(N = 520)
Mild 3 (1.7) 1 (1.3) 9 (3.4) 13 (2.5) 2 (1.1) 1 (1.3) 12 (4.6) 15 (2.9)
Moderate 8 (4.5) 3 (3.8) 6 (2.3) 17 (3.3) 7 (3.9) 2 (2.5) 8 (3.1) 17 (3.3)
Severe 2 (1.1) 1 (1.3) 1 (0.4) 4 (0.8) 0 (0) 1 (1.3) 0 (0) 1 (0.2)
* If a subject reported more than one nausea/diarrhoea event, the more severe event will be used in the analysis.
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nal distension (n = 3; 0.6%) and dizziness (n = 2; 0.4%).
The majority of these AEs were mild and moderate in
severity, with severe AEs leading to discontinuation in 3
of the 21 patients. Seventeen of 21 patients discontinued
due to a treatment-related AE, of which diarrhoea and
nausea accounted for 6 (1.2%) and 3 (0.6%) respectively.
Of the 17 patients discontinuing due to treatment related
AEs 2 were rated as severe.
Dose reductions occurred in 41 (7.9%) of the 520
patients, four of whom ultimately discontinued. The total
number of patients who either discontinued due to a
treatment-related AE or dose reduced prior to complet-
ing the study was 54 (10.4%). Signiﬁcant changes from
baseline in haematology and biochemical laboratory val-
ues, vital signs, weight, BMI and physical examination
were not seen over the duration of the study.
Patient outcomes
During the phase 3 and open-label extension periods the
overall monthly responder rates tended to increase over
time with the monthly responder rate at 16% following
1 month of lubiprostone treatment, and subsequently
ranged from 23% to 29% following 2–5 months of treat-
ment, 32–35% following 6–9 months of treatment and 37
–44% following 10–13 months of lubiprostone treatment.
These data do not include patients that dropped out dur-
ing the extension study. Age, baseline weight and IBS
subtype (as classiﬁed under Rome III) were predictive of
dropout events indicating that younger, lower body
weight patients with IBS-D (Rome III) were more likely
to dropout. These factors were used in a logistic multiple
imputation model to replace missing values. Each missing
value was imputed 25 times and the average response fre-
quency was used in the ﬁnal ﬁgure. Figure 3 presents the
responder rates with missing data imputed (522 each
month through month 9 and 341 for months 10–13). Fig-
ure 3 demonstrates that early improvements in monthly
response rates are maintained through the extension
study even when accounting for dropouts. By month 13
the responder rate is 35% in the imputed data and 44%
in the patients with complete data.
As illustrated in Figure 4 (n = 167 P/L; n = 71 L/P/L;
n = 238 L/L), mean weekly SBM frequency per month
increased following the ﬁrst month of lubiprostone treat-
ment and remained relatively stable, at approximately
ﬁve SBMs per week, with continued treatment. Within
each group, the change from baseline was signiﬁcantly
different for most months (P  0.002). Patients’ symp-
toms of abdominal discomfort and pain also improved
gradually with open-label lubiprostone treatment, with
improvements maintained with continued treatment and
ranging from approximately 0.4 after 1 month in each
of the three groups and remaining at approximately
0.7 during the remaining course of treatment (Fig-
ure 5; n = 167 P/L; n = 71 L/P/L; n = 238 L/L). The
improvement in pain scores were signiﬁcantly different
from baseline (P < 0.001) at each monthly assessment,
across all groups and throughout the study period.
Table 6 | Diarrhoea and nausea treatment-related adverse events by seriousness and severity
Diarrhoea Nausea
Description
P/L
(N = 15)
L/P/L
(N = 6)
L/L
(N = 24)
Total
(N = 45)
P/L
(N = 9)
L/P/L
(N = 7)
L/L
(N = 28)
Total
(N = 44)
Serious AEs 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Nonserious AEs 15 (100.0) 6 (100.0) 24 (100.0) 45 (100.0) 9 (100.0) 7 (100.0) 28 (100.0) 44 (100.0)
Mild 3 (20.0) 2 (33.3) 12 (50.0) 17 (37.8) 2 (22.2) 2 (28.6) 16 (57.1) 20 (45.5)
Moderate 9 (60.0) 3 (50.0) 11 (45.8) 23 (51.1) 7 (78.8) 4 (57.1) 12 (42.9) 23 (52.3)
Severe 3 (20.0) 1 (16.7) 1 (4.2) 5 (11.1) 0 (0) 1 (14.3) 0 (0) 1 (2.3)
Figure 3 | Monthly responder rates. Early improvement
in monthly responder rates were maintained through
the extension study even when accounting for drop out.
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Similar to the ratings of abdominal discomfort/pain,
the mean patient ratings for abdominal bloating and
stool consistency were signiﬁcantly improved from base-
line in all enrolment groups throughout the study period
(P < 0.001). The overall improvements in the rating of
abdominal bloating ranged from 0.45 at month 1 to
0.87 at month 13, and for stool consistency from
0.50 at month 1 to 0.68 at month 13. Patient scores
for degree of straining demonstrated overall signiﬁcant
improvements ranging from 0.58 at month 1 to 0.81
at month 13; and for constipation severity overall statis-
tically signiﬁcant improvements ranged from 0.57 at
month 1 to 0.87 at month 13.
Using a 7-point balanced scale (signiﬁcantly relieved,
moderately relieved, a little bit relieved, unchanged, a lit-
tle bit worse, moderately worse, or signiﬁcantly worse) to
Figure 4 | Summary of SBM frequency per week rates, by group. The mean SBM frequency per week increased during
the ﬁrst month of open-label lubiprostone treatment in all three treatment groups and remained relatively stable
thereafter.
Figure 5 | Abdominal discomfort/pain scores (mean). Using a scale of 0 = absent, 1 = mild, 2 = moderate, 3 = severe
and 4 = very severe, there were improvements in patients symptoms of abdominal discomfort/pain during open-label
lubiprostone treatment, with improvements maintained during the course of the extension study. 95% conﬁdence
intervals for each monthly estimate are provided.
596 Aliment Pharmacol Ther 2012; 35: 587-599
ª 2012 Blackwell Publishing Ltd
W. D. Chey et al.
assess symptom relief, the overall change from baseline
improvements ranged from 0.96 at month 1 to 1.55 at
month 13.
All groups reported similar quality of life scores at
baseline (approximately 55.9 in each group). Clinically
signiﬁcant increases in the quality of life scores (indicat-
ing improved quality of life over baseline) were observed
initially in each treatment group and maintained
throughout the study period, with the monthly average
change from baseline in treated patients shown in
Figure 6.
DISCUSSION
Lubiprostone is a member of the prostone class of com-
pounds. Pharmacologically, it acts on chloride channels
(ClC-2) to increase chloride secretion and the passive
transport of sodium and water across gastrointestinal
mucosal epithelia,12–14 thereby enhancing transit and
ameliorating the symptoms of constipation. Furthermore,
recent evidence suggests that some patients with IBS
have increased intestinal permeability.15 Data from
recent animal studies suggests that lubiprostone may
restore abnormal mucosal barrier function induced by is-
chaemic injury.13, 14 Two clinical trials recently assessed
the efﬁcacy of lubiprostone for the treatment of IBS-C in
adults.8 The combined results from these two phase 3
trials provide support for the efﬁcacy of lubiprostone in
the treatment of the global and individual symptoms
experienced by patients with IBS-C. Based upon results
from these studies, lubiprostone (8 mcg) was approved
by the FDA for the treatment of IBS-C in adult women
in April 2008.
The primary objective of this open-label, extension
study was to determine the long-term safety of a 16 mcg
(8 mcg twice daily) dose of lubiprostone, when adminis-
tered for 36 weeks in patients with IBS-C who had
already received between 12–16 weeks of lubiprostone
treatment. Overall, the long-term use of lubiprostone
demonstrated a favourable safety proﬁle. The most com-
mon AEs reported by >5% of patients were diarrhoea
(11.0%), nausea (11.0%), urinary tract infection (9.0%),
sinusitis (9.0%) and abdominal distension (5.8%).
Approximately 25% of patients in this extension study
reported an AE that was thought to be treatment-related.
The majority of these treatment-related AEs were mild
to moderate in severity, and none were rated to be seri-
ous. The most common treatment-related events
reported by >1% of patients were diarrhoea, nausea,
abdominal distention, abdominal pain, ﬂatulence,
abdominal pain upper, headache, dizziness and vomiting
affecting between 1% and 6.5% of lubiprostone patients.
The majority of events in patients with treatment-related
diarrhoea and nausea were mild to moderate in severity
with severe treatment-related diarrhoea and nausea
reported by 4 (0.8%) and 1 (0.2%) of the 520 patients
respectively. It should be noted that the extension study
was designed to reﬂect ‘real world’ clinical practice, and
there was no formal assessment by questionnaire, or
otherwise, for speciﬁc AEs. As such, the AE data are
potentially subject to over- or under-reporting. The inci-
dence and type of treatment-related AEs (approximately
25%) observed in this long-term open-label extension
study (36 weeks) were similar to the incidence rate
(22%) and type reported for lubiprostone patients in the
Figure 6 | Monthly change from baseline in overall quality of life by treatment group (ITT patients). At baseline,
comparable quality of life scores were reported in each of the three groups (55.9 ± 21.7, P/L; 55.6 ± 22.3, L/P/L, and
55.9 ± 20.9, L/L). All three treatment groups exhibited improvements in their quality of life with continued open-label
lubiprostone treatment.
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earlier two 12 to 16-week phase 3 studies.8 The 25%
incidence of treatment-related AEs observed in this
open-label study of 8 mcg lubiprostone was less than the
36% reported in a previous study using 24 mcg twice
daily of patients with chronic constipation16; similarly,
the treatment-related incidence rate for nausea was 6.3%
for all patients in this study, compared with nearly 32%
in the higher-dose study.16 These ﬁndings suggest a dose
response relationship between lubiprostone and the inci-
dence of AEs. It should also be noted that the percentage
of patients on placebo reporting an AE and treatment-
related AE of nausea in the pivotal phase 3 studies was
5.7% and 3.6% respectively; suggesting that some inci-
dences of nausea reported in this study may be attribut-
able to the patients IBS-C. Post hoc analysis revealed that
moderate to severe nausea occurred in 3.5% of patients
in the current study, with no difference between patients
by prior treatment group. Of the 44 treatment-related
episodes of nausea reported, the majority of patients
(84.4%) had only one episode. Kaplan–Meier analysis,
for time to nausea onset, estimates that 67% of nausea
episodes occurred within the ﬁrst week of treatment; a
repeated time to event analysis further demonstrated that
there was no relationship between time of nausea onset
and whether or not the patient had received prior lubi-
prostone treatment. Ten per cent (n = 54) of patients
either discontinued due to a treatment-related AE or
dose reduced prior to completing the study, indicating
that lubiprostone was well-tolerated with respect to AEs.
Treatment efﬁcacy data from this long-term, open-
label study should be interpreted with caution. The
absence of a placebo arm, regression to the mean and
patient attrition during the study period complicate the
interpretation of this data. Multiple imputation was
used to address the limitation of attrition in the
responder analysis. There was little difference in the
monthly responder estimates between the complete
cases and imputed analysis through 9 months. After
9 months patients who remained in the study had a
substantially higher response than estimated using the
imputed data. The data indicates that younger patients,
those with lower rate, or components of diarrhoea were
more likely to discontinue treatment. Acknowledging
these limitations, patients enrolled in this study experi-
enced signiﬁcant sustained improvements from baseline
in their IBS-C associated symptoms including frequency
of SBMs, abdominal pain/discomfort, abdominal bloat-
ing, stool consistency, bowel straining, constipation
severity and symptom relief. Of interest, a post hoc
analysis revealed that the only patient-reported factor
from the week prior to entry into the extension study
that was predictive of continued use of lubiprostone
and completion of the extension study was symptom
relief. Patients who did not complete the extension
study reported an average symptom relief score of 0.28
at the end of the phase 3 double-blind period, com-
pared with 0.93 reported by patients going on to com-
plete the long-term study (P = 0.0012). A total of 63–
79% of the patients who reported symptom relief at the
end of the double-blind period completed the extension
study. A similar relationship between symptom relief
and completion of the long-term study was also
observed at 1 month into the extension study
(p  0.0001). The improvements in IBS-C signs and
symptoms are consistent with a recently published
phase 2 trial of patients with IBS-C treated with lubi-
prostone at doses of 8, 16 and 24 mcg, administered
twice daily.17 In this study of 195 patients, signiﬁcant
improvements compared with placebo for abdominal
pain/discomfort, abdominal bloating, frequency of
SBMs, stool consistency, bowel straining and constipa-
tion severity were observed.
As noted earlier, individuals with IBS have substantial
decrements in their quality of life as well as their ability
to perform activities of daily living. In addition, to the
sustained signiﬁcant improvements in IBS-C symptoms
reported with long-term lubiprostone treatment, patients
also reported clinically signiﬁcant improvements from
baseline (P  0.026) in quality of life scores throughout
the study period.
In conclusion, the current long-term, open-label
extension study demonstrates that lubiprostone, when
given for 9–13 months in patients with IBS-C has a
favourable safety and tolerability proﬁle and provides
preliminary evidence for the efﬁcacy of lubiprostone in
the long-term treatment of IBS-C.
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